Intervention

Laquinimod

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials8

Recruiting0

Common conditions4

Lead sponsors shown2

Clinical trials

8 shown

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to PlaceboNCT02284568 · 2015-01-12

COMPLETED

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)NCT01975298 · 2014-01-01

WITHDRAWN

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)NCT01707992 · 2013-02-20

COMPLETED

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple SclerosisNCT01047319 · 2010-05-27

TERMINATED

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease CourseNCT00988052 · 2009-11-10

TERMINATED

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)NCT00605215 · 2008-04-24

COMPLETED

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)NCT00509145 · 2007-11-13

COMPLETED

An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the DiseaseNCT00745615 · 2005-12-07

TERMINATED

Common conditions

Multiple Sclerosis3 Relapsing Multiple Sclerosis2 Relapsing Remitting Multiple Sclerosis2 Primary Progressive Multiple Sclerosis1

Mapped diseases appearing in these trials

Shared study participation does not establish that this intervention treats a disease.

multiple sclerosis3 primary progressive multiple sclerosis1 relapsing-remitting multiple sclerosis1

Leading sponsors

Teva Branded Pharmaceutical Products R&D, Inc. 7 Teva Pharmaceutical Industries, Ltd. 1

Trial status mix

COMPLETED4

TERMINATED3

WITHDRAWN1

Phase mix

PHASE36

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.